未登录 A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer 一项关于JNJ-87189401(PSMA-CD28双特异性抗体)联合JNJ-78278343(KLK2-CD3双特异性抗体)治疗晚期前列腺癌的安全性、耐受性及初步疗效的I期、首次人体试验、开放标签、多中心、进行中的临床试验。 Stein, M. N.; Graham, L. S.; Baldini, C.; Vinceneux, A.; Kessler, E.; Runcie, K.; Wei, A. Z.; Papadopoulos, K. P.; Bernard-Tessier, A.; Laurent, M.; Jaiprasart, P.; Thaper, D.; Shen, F.; Cartee, L.; Attiyeh, E.; Villalobos, V. M.; Rasco, D. 分享 收藏
Translational PK/PD and model-informed development of JNJ-67842125, a Fab reversal agent for JNJ-64179375, a long-acting thrombin inhibitor Ayyar, Vivaswath S.; Jaiprasart, Pharavee; Geist, Brian; Huang Devine, Zheng; Case, Martin; Hazra, Anasuya; Hsu, Chyi-Hung; Chintala, Madhu; Wang, Weirong 分享 收藏
分享 收藏
Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis Neelakantan, Deepika; Dogra, Samrita; Devapatla, Bharat; Jaiprasart, Pharavee; Mukashyaka, Marie Claire; Janknecht, Raif; Dwivedi, Shailendra Kumar Dhar; Bhattacharya, Resham; Husain, Sanam; Ding, Kai; Woo, Sukyung 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏